Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 3
2020 4
2021 14
2022 11
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, Koga H, Torimura T. Suzuki H, et al. Among authors: kamachi n. Cancer Commun (Lond). 2023 Apr;43(4):415-434. doi: 10.1002/cac2.12411. Epub 2023 Feb 24. Cancer Commun (Lond). 2023. PMID: 36825684 Free PMC article.
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: kamachi n. Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16. Hepatol Res. 2023. PMID: 36316794
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Shimose S, et al. Among authors: kamachi n. Sci Rep. 2022 Oct 11;12(1):17018. doi: 10.1038/s41598-022-21528-2. Sci Rep. 2022. PMID: 36220865 Free PMC article.
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: kamachi n. Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6. Hepatol Res. 2023. PMID: 36149726
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: kamachi n. Cancers (Basel). 2022 Sep 1;14(17):4284. doi: 10.3390/cancers14174284. Cancers (Basel). 2022. PMID: 36077816 Free PMC article.
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.
Suzuki H, Iwamoto H, Shimose S, Niizeki T, Shirono T, Noda Y, Kamachi N, Yamaguchi T, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Suzuki H, et al. Among authors: kamachi n. Front Oncol. 2022 Jul 22;12:948293. doi: 10.3389/fonc.2022.948293. eCollection 2022. Front Oncol. 2022. PMID: 35936693 Free PMC article.
Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T. Shirono T, et al. Among authors: kamachi n. Hepatol Commun. 2022 Sep;6(9):2594-2604. doi: 10.1002/hep4.2016. Epub 2022 Jun 3. Hepatol Commun. 2022. PMID: 35656864 Free PMC article.
Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-Hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, Koga H, Torimura T. Kuromatsu R, et al. Among authors: kamachi n. Cancers (Basel). 2022 May 4;14(9):2295. doi: 10.3390/cancers14092295. Cancers (Basel). 2022. PMID: 35565424 Free PMC article.
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis.
Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T. Zaizen Y, et al. Among authors: kamachi n. Cancers (Basel). 2021 Oct 21;13(21):5282. doi: 10.3390/cancers13215282. Cancers (Basel). 2021. PMID: 34771452 Free PMC article.
29 results